Empowering labs with sample-to-report solutions for cancer genomic testing.

What we do

Contextual Genomics is a global genomics technology development company that enhances cancer care and empowers laboratory testing facilities. We distribute our patented Next-Generation Sequencing tests and computational systems worldwide to partner laboratories for transformative and enhanced cancer management practices.

Your value
Guiding clinical cancer care with genomic information.

Integrating cancer mutation information into clinical care allows molecular diagnosis information to be used where and when it is most needed—for disease management. More than 50 new drugs can only be administered to patients on the basis of knowing the status of specific gene mutations in the patient’s tumour tissue. To enable robust detection of mutations, our products are embedded with our patented molecular and computational quality assurance platform QUALITY NEXUS™. We implement end to end solutions from tumour sample through to issuing clinical reports for our partner laboratories.

Our Method
Transferring our technology to your local laboratory.

We deliver our tests to be deployed on site and branded by local partner facilities through an established technology transfer process. This enables and empowers our partners to implement a ‘full-stack’ leading-edge solution for their patients from sample accessioning through to generation of clinical report. For each partner, our technology transfer process is customized to local business and medical needs.

Learning from Data
Analytics over large datasets leads to enhanced products.

Our centralised cloud based informatics platform allows for remote and real time monitoring of laboratory performance and the ability to learn from patterns in aggregated datasets. These in turn inform enhanced product development to further benefit patients.

Why are we doing this

Cancer is a genomic disease. Cancers evolve over time.

Cancer is a disease of the genome and develops through the acquisition of mutations in otherwise normal cells. The detection of mutations across the genomes of cancer cells reveals targeted treatment options for patients for which they would otherwise be ineligible. Furthermore, our tests monitor evolution of cancers through analysis of tumour DNA in the patient’s blood. These DNA signals analyzed over time may indicate a patient’s disease is changing, thus requiring alternate treatment options.